Last reviewed · How we verify
cyclobenzaprine ER (AMRIX) — Competitive Intelligence Brief
marketed
Muscle relaxant (centrally acting)
Brainstem monoamine receptors (non-selective); structurally related to tricyclic antidepressants
Neurology / Musculoskeletal
Small molecule
Live · refreshed every 30 min
Target snapshot
cyclobenzaprine ER (AMRIX) (cyclobenzaprine ER (AMRIX)) — State University of New York - Upstate Medical University. Cyclobenzaprine is a centrally acting muscle relaxant that reduces muscle tension by depressing activity in the brainstem.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| cyclobenzaprine ER (AMRIX) TARGET | cyclobenzaprine ER (AMRIX) | State University of New York - Upstate Medical University | marketed | Muscle relaxant (centrally acting) | Brainstem monoamine receptors (non-selective); structurally related to tricyclic antidepressants |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Muscle relaxant (centrally acting) class)
- Express Specialty Pharmacy · 1 drug in this class
- State University of New York - Upstate Medical University · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- cyclobenzaprine ER (AMRIX) CI watch — RSS
- cyclobenzaprine ER (AMRIX) CI watch — Atom
- cyclobenzaprine ER (AMRIX) CI watch — JSON
- cyclobenzaprine ER (AMRIX) alone — RSS
- Whole Muscle relaxant (centrally acting) class — RSS
Cite this brief
Drug Landscape (2026). cyclobenzaprine ER (AMRIX) — Competitive Intelligence Brief. https://druglandscape.com/ci/cyclobenzaprine-er-amrix. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab